Performance of the Aspergillus Galactomannan Lateral Flow Assay with a Digital Reader for the Diagnosis of Invasive Aspergillosis: a Multicenter Study

Overview

Journal Eur J Clin Microbiol Infect Dis

Publisher Springer

Specialties Infectious Diseases
Microbiology

Date 2023 Nov 29

PMID 38030860

Authors

Jian Guo

Chenlu Xiao

Wenjie Tian

Li Lv

Liang Hu

Lijun Ni

Dongjiang Wang

Wei Li

Dan Qiao

Wenjuan Wu

Affiliations

Soon will be listed here.

Abstract

Purpose: The objective of this multicenter study was to compare the diagnostic performance of lateral flow assay (LFA) and enzyme-linked immunosorbent assay (ELISA) to detect the Dynamiker Aspergillus Galactomannan levels in serum and bronchoalveolar lavage fluid (BALF) samples for I.

Methods: We registered 310 clinically suspected Aspergillus infection patients from December 2021 to February 2023 and classified them into subgroups as the "IA group" and "non-IA group" based on the latest EORTC/MSG guidelines. The immunoassays were analyzed by LFA and ELISA respectively.

Results: Galactomannan was examined using LFA, and serum and BALF samples demonstrated sensitivities of 82.57% and 89.47%, specificities of 90.76% and 92.00%, PPVs of 89.11% and 96.23%, and NPVs of 85.04% and 79.31%, respectively. Galactomannan was observed using two assays in serum and BALF samples and showed PPAs of 95.11% and 93.33%, NPAs of 89.19% and 96.30%, and TPAs of 92.47% and 94.25%, respectively. The ROC curve demonstrated that LFA had optimum diagnostic value when the index value (I value) = 0.5, the sensitivity was 84.94%, and the specificity was 90.97%.

Conclusion: Compared to the ELISA method, the LFA has shown excellent performance for the diagnosis of IA in serum and BALF sample and can be used as an assay for the early diagnosis of patients with IA. The dynamic change in galactomannan levels may be useful for assessing treatment response.

Citing Articles

An Observational Cohort Study of Bronchoalveolar Lavage Fluid Galactomannan and Culture Positivity in Patients Requiring Mechanical Ventilation.

Gao C, Markov N, Pickens C, Pawlowski A, Kang M, Walter J Open Forum Infect Dis. 2025; 12(3):ofaf090.

PMID: 40046892 PMC: 11879572. DOI: 10.1093/ofid/ofaf090.

Diagnostic Approach to Pneumonia in Immunocompromised Hosts.

Ullah N, Fusco L, Ametrano L, Bartalucci C, Giacobbe D, Vena A J Clin Med. 2025; 14(2).

PMID: 39860395 PMC: 11765643. DOI: 10.3390/jcm14020389.

References

Susianti H, Parmadi L, Firani N, Setyawan U, Sartono T . Diagnostic value of serum human Galactomannan aspergillus antigen and 1,3-beta-D-glucan in immunocompromised patient suspected fungal infection. J Clin Lab Anal. 2021; 35(6):e23806. PMC: 8183930. DOI: 10.1002/jcla.23806. View

Lamoth F . Galactomannan and 1,3-β-d-Glucan Testing for the Diagnosis of Invasive Aspergillosis. J Fungi (Basel). 2018; 2(3). PMC: 5753135. DOI: 10.3390/jof2030022. View

Bassetti M, Giacobbe D, Grecchi C, Rebuffi C, Zuccaro V, Scudeller L . Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, adult patients: A systematic review with qualitative evidence synthesis. J Infect. 2020; 81(1):131-146. DOI: 10.1016/j.jinf.2020.03.065. View

Mercier T, Dunbar A, de Kort E, Schauwvlieghe A, Reynders M, Guldentops E . Lateral flow assays for diagnosing invasive pulmonary aspergillosis in adult hematology patients: A comparative multicenter study. Med Mycol. 2019; 58(4):444-452. DOI: 10.1093/mmy/myz079. View

White P, Price J, Posso R, Cutlan-Vaughan M, Vale L, Backx M . Evaluation of the Performance of the IMMY sona Galactomannan Lateral Flow Assay When Testing Serum To Aid in Diagnosis of Invasive Aspergillosis. J Clin Microbiol. 2020; 58(6). PMC: 7269407. DOI: 10.1128/JCM.00053-20. View

Zhang L, Che C . Clinical manifestations and outcome analysis of invasive pulmonary aspergillosis infection: a retrospective study in 43 nonneutropenic patients. J Int Med Res. 2019; 47(11):5680-5688. PMC: 6862873. DOI: 10.1177/0300060519874901. View

White P, Price J, Posso R, Vale L, Backx M . An Evaluation of the Performance of the IMMY Galactomannan Enzyme-Linked Immunosorbent Assay When Testing Serum To Aid in the Diagnosis of Invasive Aspergillosis. J Clin Microbiol. 2020; 58(12). PMC: 7685879. DOI: 10.1128/JCM.01006-20. View

Almeida-Paes R, Almeida M, de Macedo P, Caceres D, Zancope-Oliveira R . Performance of Two Commercial Assays for the Detection of Serum Galactomannan in Non-Neutropenic Patients. J Fungi (Basel). 2022; 8(7). PMC: 9320752. DOI: 10.3390/jof8070741. View

Zhou L, Jiang Y, Li R, Huang L, Yip C, Denning D . Risk-Based Estimate of Human Fungal Disease Burden, China. Emerg Infect Dis. 2020; 26(9):2137-2147. PMC: 7454105. DOI: 10.3201/eid2609.200016. View

10.

Jenks J, Mehta S, Taplitz R, Aslam S, Reed S, Hoenigl M . Point-of-care diagnosis of invasive aspergillosis in non-neutropenic patients: Aspergillus Galactomannan Lateral Flow Assay versus Aspergillus-specific Lateral Flow Device test in bronchoalveolar lavage. Mycoses. 2018; 62(3):230-236. PMC: 6380940. DOI: 10.1111/myc.12881. View

11.

Serin I, Dogu M . Serum Aspergillus galactomannan lateral flow assay for the diagnosis of invasive aspergillosis: A single-centre study. Mycoses. 2021; 64(6):678-683. DOI: 10.1111/myc.13265. View

12.

Liu F, Zhang X, Du W, Du J, Chi Y, Sun B . Diagnosis values of IL-6 and IL-8 levels in serum and bronchoalveolar lavage fluid for invasive pulmonary aspergillosis in chronic obstructive pulmonary disease. J Investig Med. 2021; 69(7):1344-1349. DOI: 10.1136/jim-2021-001857. View

13.

Patterson T, Thompson 3rd G, Denning D, Fishman J, Hadley S, Herbrecht R . Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016; 63(4):e1-e60. PMC: 4967602. DOI: 10.1093/cid/ciw326. View

14.

Wang C, Xu J, Yang L, Xu Y, Zhang X, Bai C . Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018; 391(10131):1706-1717. DOI: 10.1016/S0140-6736(18)30841-9. View

15.

Linder K, Kauffman C, Miceli M . Performance of Galactomannan Lateral Flow Assay on Bronchoalveolar Lavage Fluid for the Diagnosis of Invasive Pulmonary Aspergillosis. J Fungi (Basel). 2020; 6(4). PMC: 7711466. DOI: 10.3390/jof6040297. View

16.

Jenks J, Hoenigl M . Point-of-care diagnostics for invasive aspergillosis: nearing the finish line. Expert Rev Mol Diagn. 2020; 20(10):1009-1017. DOI: 10.1080/14737159.2020.1820864. View

17.

Donnelly J, Chen S, Kauffman C, Steinbach W, Baddley J, Verweij P . Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2019; 71(6):1367-1376. PMC: 7486838. DOI: 10.1093/cid/ciz1008. View

18.

Jenks J, Mehta S, Taplitz R, Law N, Reed S, Hoenigl M . Bronchoalveolar lavage Aspergillus Galactomannan lateral flow assay versus Aspergillus-specific lateral flow device test for diagnosis of invasive pulmonary Aspergillosis in patients with hematological malignancies. J Infect. 2018; 78(3):249-259. DOI: 10.1016/j.jinf.2018.10.014. View

19.

Cordonnier C, Botterel F, Ben Amor R, Pautas C, Maury S, Kuentz M . Correlation between galactomannan antigen levels in serum and neutrophil counts in haematological patients with invasive aspergillosis. Clin Microbiol Infect. 2009; 15(1):81-6. DOI: 10.1111/j.1469-0691.2008.02122.x. View

20.

Heldt S, Eigl S, Prattes J, Flick H, Rabensteiner J, Pruller F . Levels of interleukin (IL)-6 and IL-8 are elevated in serum and bronchoalveolar lavage fluid of haematological patients with invasive pulmonary aspergillosis. Mycoses. 2017; 60(12):818-825. DOI: 10.1111/myc.12679. View